3M Company (MMM) - Q3 2007 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2007. 3M is a diversified global manufacturer organized into six operating segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, and Electro and Communications. Effective in Q1 2007, the company reorganized its business segments to align better with markets and customers. The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Q3 2007 | Q3 2006 | YTD 9M 2007 | YTD 9M 2006 |
|---|---|---|---|---|
| Net Sales | $6,177 million | $5,858 million | $18,256 million | $17,141 million |
| Operating Income | $1,425 million | $1,342 million | $4,923 million | $3,886 million |
| Net Income | $960 million | $894 million | $3,245 million | $2,675 million |
| Diluted EPS | $1.32 | $1.18 | $4.42 | $3.50 |
| Operating Margin | 23.1% | 22.9% | 27.0% | 22.7% |
| Operating Cash Flow (9M) | $2,719 million (vs. $2,517 million prior year) | |||
| Total Debt | $5,229 million (as of Sept 30, 2007) | |||
| Cash & Equivalents | $1,675 million (as of Sept 30, 2007) | |||
| Debt to Total Capital | 32% (as of Sept 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 5.5% in Q3 and 6.5% YTD. Local-currency sales growth was 6.3% in Q3, driven by organic volume growth of 4.2% and acquisitions of 2.1%. Divestitures, primarily the sale of the global branded pharmaceuticals business, reduced sales growth by 3.9%.
- Profitability: Operating income increased 6.2% in Q3. YTD operating margins expanded to 27.0% (from 22.7% in 2006), significantly boosted by a $854 million pre-tax gain on the sale of businesses (pharmaceuticals and Opticom/Canoga) and a $52 million gain on real estate sales.
- Cost Structure: Cost of sales as a percent of net sales increased 1.3 percentage points in Q3, largely due to the divestiture of the low-cost-of-sales pharmaceutical business. SG&A expenses as a percent of sales decreased 1.2 percentage points.
- Debt & Liquidity: Total debt increased to $5.229 billion from $3.553 billion at year-end 2006, driven by a $750 million 30-year note issuance in March and a 750 million Euro bond issuance in July. These proceeds were partially used to fund share repurchases.
Guidance, Outlook, and Risks
- Capital Allocation: The Board approved a $7.0 billion two-year share repurchase authorization in February 2007. As of September 30, approximately $4.6 billion remained available. The company also increased its quarterly dividend by 4.3% to $0.48 per share, marking the 49th consecutive year of dividend increases.
- Outlook: Management expects capital expenditures to total approximately $1.4 to $1.5 billion for the full year 2007. Stock-based compensation expense is expected to total $0.18 per diluted share in 2007.
- Segment Performance: Health Care sales were down 3.7% due to the pharmaceutical divestiture, though the remaining Health Care business grew 20.6%. Safety, Security and Protection Services grew 10.9% driven by acquisitions. Display and Graphics faced softness in LCD monitor and TV attachment rates due to competition.
- Risks & Contingencies:
- Legal Proceedings: Significant exposure remains regarding respirator mask/asbestos litigation (approx. 12,600 claimants) and environmental matters related to perfluorooctanyl compounds (PFOA/PFOS). The company increased environmental liabilities by $134 million YTD.
- Liquidity Risk: $34 million of the company's marketable securities portfolio (auction rate securities) failed to auction in Q3. While rated AAA, these funds are temporarily inaccessible. An $8 million temporary impairment was recorded in AOCI.
- Market Conditions: Weakness in the U.S. housing market impacted industrial minerals and protective materials. Consumer electronics markets remain sluggish.
Investor Verification Checklist
- Divestiture Impact: Verify the sustainability of operating margins excluding the $854 million one-time gain on the sale of the pharmaceutical business and other divestitures.
- Environmental Liabilities: Review the $134 million increase in environmental reserves related to PFOA/PFOS contamination and the potential for future regulatory costs in Minnesota and Alabama.
- Auction Rate Securities: Assess the liquidity risk associated with the $34 million in failed auction rate securities and the timeline for potential recovery.
- Asbestos Litigation: Monitor the trend in respirator mask/asbestos claims, noting the shift from unimpaired claimants to more serious injury claims which may increase average resolution costs.
- Share Repurchase Execution: Track the utilization of the remaining $4.6 billion repurchase authorization and its impact on diluted EPS.